Study guide

12.1 Domain-by-Domain Quick Review

PTCB Hazardous Drug Management Certificate Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

0.1 Exam Facts, Format & Eligibility 0.2 Content Outline, Scoring & Registration 0.3 USP <800> Big Picture & How to Use This Guide

2 USP <800> Program Administration

1.1 USP <800> Scope, Purpose & Enforcement 1.2 The NIOSH Hazardous Drug List (2024 Update) 1.3 Assessment of Risk 1.4 Designated Person, SOPs & the Hierarchy of Controls

3 Training, Compliance & Recordkeeping

2.1 Training Requirements & Medical Surveillance 2.2 Hazard Communication, SDS & OSHA Requirements 2.3 Recordkeeping & Professional Guidelines

4 Primary Engineering Controls

3.1 Containment Primary Engineering Controls (C-PEC): BSCs & CACIs 3.2 Closed System Transfer Devices (CSTDs) 3.3 Nonsterile Controls and the C-SCA Distinction

5 Secondary Engineering Controls & Facility Design

4.1 Containment Secondary Engineering Controls (C-SEC): Negative Pressure & Air Exchange 4.2 Facility Layout: Storage, Unpacking & Sink Placement 4.3 Certification, ISO Classes & Emergency Equipment

6 Facility Cleaning Procedures

5.1 The Four-Step Cleaning Process 5.2 Wipe Sampling & Action Levels 5.3 Hazardous Waste Disposal & RCRA

7 Spill Response & Cleaning PPE

6.1 Spill Kits & Spill Response Procedures 6.2 PPE During Cleaning: Glove Change Frequency & Disposal

8 Dispensing & the Compounding Interface

7.1 USP <795>/<797> Interface for Hazardous Drugs 7.2 High-Risk Oral Hazardous Drugs 7.3 Tablet Splitting & Crushing Restrictions

9 Counting, Packaging & Patient Counseling

8.1 Counting, Packaging & Dedicated Equipment 8.2 Patient Counseling & Unit-Dose Labeling

10 PPE: Gloves, Gowns & Task-Based Selection

9.1 ASTM D6978 Chemotherapy Gloves & Double Gloving 9.2 Chemo Gowns & Gown Change Frequency 9.3 Task-Based PPE Selection

11 Respiratory Protection, Eye Protection & PPE Sequencing

10.1 Respiratory & Eye/Face Protection 10.2 Donning & Doffing Sequence

12 Transport & Receiving

11.1 Receiving Hazardous Drug Shipments 11.2 Internal Transport & Storage 11.3 Damaged/Leaking Shipments & Chain of Custody

13 Exam Readiness & Final Review

12.1 Domain-by-Domain Quick Review 12.2 Common Exam Traps & Final Checklist

12.1 Domain-by-Domain Quick Review

Key Takeaways Explain This Topic AI

The official weights are Engineering Controls 22%, Administrative 22%, Facility Cleaning 16%, Dispensing Final Dosage Forms 16%, PPE 13% and Transport & Receiving 11%.

AoR eligibility depends on the specific HD, dosage form and activity; it is not correctly described as a blanket ban on every compounding-related scenario.

Match air-change and containment requirements to the room: nonsterile HD C-SEC 12 ACPH, ISO Class 7 sterile HD buffer 30 ACPH; a C-SCA is a distinct Category 1 setting.

HD compounding requires the specified gown, head/hair protection, two shoe-cover pairs and two ASTM D6978-tested glove pairs; other activities need their applicable protection.

Use current USP guidance for deactivation, compatible CSTD administration and recommended sampling; investigate and document contamination findings.

Last updated: October 2026

Review all six official domains

The PTCB Hazardous Drug Management content outline defines six domains. Use their weights to organise a review, then adjust for the errors you actually make. A domain's percentage is a blueprint share, not a promise of an exact item count on your form or evidence that a particular fact is the most frequently tested.

  • Official domain Weight Review focus
  • Engineering Controls 22% Facilities and controls for receiving, storage and manipulation
  • Facility Cleaning 16% Deactivation, decontamination, cleaning, disinfection, spills and exposure response
  • Personal Protective Equipment (PPE) 13% Selecting, using and disposing of PPE for the activity
  • Transport & Receiving 11% Transport conditions, receipt and damaged shipping containers

Dispensing Final Dosage Forms 16% NIOSH criteria and tables, supplemental controls and administration techniques

Administrative 22% Waste requirements, surveillance, wipe sampling, SOPs, training and competency

The weights total 100% . Engineering Controls and Administrative together account for 44% ; Cleaning and Dispensing total 32% ; PPE and Transport & Receiving total 24% . These arithmetic groupings are useful study-planning aids, not separate official domains. A small domain still needs review, particularly if your error log shows a weakness there.

Engineering Controls: distinguish the device from the room

A containment primary engineering control (C-PEC) controls the immediate handling environment, while the containment secondary engineering control (C-SEC) is the surrounding containment space. A closed-system drug-transfer device is supplemental; it does not replace a required C-PEC or room.

Sterile HD compounding requires the appropriate externally vented C-PEC providing ISO Class 5 or better air quality. Suitable nonsterile controls must protect personnel and the environment; nonsterile preparation does not automatically require the same ISO-classified critical environment as sterile preparation.

Keep the room configurations distinct. The chapter specifies at least 12 air changes per hour (ACPH) for the nonsterile HD compounding C-SEC and at least 30 ACPH for an ISO Class 7 sterile HD buffer room. An unclassified containment segregated compounding area (C-SCA) has a different configuration, including at least 12 ACPH; the January 2026 USP FAQ limits its sterile preparations to Category 1 . The required C-SEC pressure is 0.01–0.03 inches of water below adjacent areas . Match the figure to the setting instead of applying one number to every room.

Administrative: evaluate the actual drug, form and activity

An assessment of risk (AoR) is specific to the drug and dosage form, considering exposure, packaging and manipulation. A whole-table label is not a substitute for that assessment. The January 2026 USP FAQ identifies mandatory containment requirements for HD active pharmaceutical ingredients (APIs) and NIOSH Table 1 antineoplastics requiring HD manipulation.

The FAQ also permits documented, implemented alternatives for eligible final dosage forms, including final forms of compounded HD preparations, and for appropriate other HD dosage forms. It explicitly allows consideration of reconstitution, mixing and dilution of NIOSH Table 2 dosage forms under an AoR. Thus “any compounding makes AoR impossible” is too broad, while “an AoR can waive every containment requirement” is also wrong. Check the specific eligibility and manufacturer conditions.

Training must precede independent handling and competency must be reassessed at least every 12 months. Maintain current, reviewed SOPs and relevant records. USP recommends medical surveillance and environmental wipe sampling; a recommendation may be supplemented by applicable law or facility requirements, but is not itself a universal USP mandate.

Facility Cleaning: preserve the purpose of each step

Deactivation renders a compound inactive; decontamination removes HD residue; cleaning removes organic and inorganic material. Disinfection follows cleaning where the sterile environment requires it. Killing microorganisms does not establish that hazardous chemical residue has been removed.

USP's current FAQ says to check HD labelling for a specific deactivation agent and, if none is listed, use an EPA-registered oxidizer . Lack of a named drug-specific agent does not automatically justify omitting deactivation. Select products suitable for the intended use and surface, following their instructions; no single agent is established as effective for every HD.

If a wipe result indicates contamination, identify and address the cause, document the action and evaluate whether the response worked. Retraining, work-practice changes and containment improvements may be needed alongside appropriate surface treatment. A higher room air-change rate alone does not remove residue from a work surface.

PPE: use the task-specific requirements

The January 2026 FAQ specifies gowns, head and hair covers, two pairs of shoe covers and two pairs of ASTM D6978-tested gloves for sterile and nonsterile HD compounding. For administration of NIOSH Table 1 antineoplastic HDs it specifies two pairs of chemotherapy gloves, with an HD-resistant gown also required for injectable administration. Other activities require the PPE specified through the facility's applicable safety plan, risk assessment and SOPs.

Do not turn an intact-dosage-form example into a universal “one glove is enough” rule. Receiving, counting, cleaning and dealing with damaged packages have different exposure conditions. Eye, face and respiratory protection depend on the activity and exposure risk; a surgical mask is not a substitute for required respiratory protection.

Dispensing: connect the NIOSH list with the specific rule

The 2024 NIOSH list has two tables. Table 1 includes drugs with manufacturer's special handling information and/or specified NTP or IARC carcinogen classifications. It is not simply a list of all cancer medicines, and not every Table 1 drug is an antineoplastic. Table 2 also contains hazardous drugs; placement there does not mean a drug is harmless.

For USP's specific antineoplastic provisions, retain the Table 1 antineoplastic qualifier. A compatible CSTD is required during their administration when the dosage form allows; CSTD use for compounding is recommended by the chapter. Verify physical and chemical compatibility and retain the other necessary controls.

Intact final dosage forms differ from particle-generating manipulation. For example, crushing a Table 1 antineoplastic tablet is not equivalent to counting an intact unit. A finished dosage form's existence does not by itself authorise uncontained manipulation.

Transport and Receiving: respond to the condition presented

Use transport containers that minimise breakage and leakage. The current USP FAQ prohibits pneumatic tubes for any liquid HD or any NIOSH Table 1 antineoplastic HD . Apply the actual classification and dosage-form conditions rather than a blanket rule about every medicine.

Unpacking must occur in the appropriate receiving area, not a sterile compounding area. The relevant Table 1 antineoplastic and HD API unpacking areas must be neutral or negative relative to their surroundings. A suspected damaged package needs the facility's trained response and appropriate PPE; do not assume its contents are intact because the damage is not yet visible.

For a final practice review, identify the action first: receiving, storing, manipulating, administering, cleaning or disposing. Then identify the drug, dosage form, containment setting and relevant SOP. This sequence helps distinguish a correct conditional rule from a statement that has lost an essential qualifier.